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Abstract: Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the
tumor immune microenvironment and have been shown to provide prognostic and predictive
biomarkers. The extent of lymphocytic infiltration in tumor tissues can be assessed by evaluating
hematoxylin and eosin (H&E)-stained tumor sections. We investigated tissue microarrays of 31
invasive breast cancer patients, looking at quantity and topological distribution of CD3+, CD8+,
CD20+, Ki67+, FoxP3+ TILs and CD3+/FoxP3+, CD8+/FoxP3+ cell ratios. We separately evaluated
TILs at the invasive edge and at the center of the tumor, to find any clinical implications of tumor
heterogeneity. No statistically significant difference was found in quantity and distribution of both
TIL subsets and TIL ratios, by comparing patients who suffered from a local or distant recurrence
of the tumor (relapse group: 13 patients) with patients not showing cancer relapse (non-relapse
group: 18 patients). In the whole sample, we observed three main statistically significant positive
correlations: (1) between CD3+ and CD8+ T-cells; (2) between FoxP3+ and Ki67+ lymphocyte
infiltration; (3) between CD3+/FoxP3+ cell ratio (C3FR) and CD8+/FoxP3+ cell ratio (C8FR). Tumor
heterogeneity and stronger positive TIL associations were found in the non-relapse group, where both
CD3–CD8 and FoxP3-Ki67 inter-correlations were found to be significant at the center of the tumor,
while the correlation between C3FR and C8FR was significant at the invasive edge. No correlations
between TIL subsets were detected in the relapse group. Our findings suggest the existence of
stronger inter-subtype lymphocytic networks in invasive breast cancer not showing recurrence.
Further evaluations of clinical and topological correlations between and within TIL subsets are
needed, in addition to the assessment of TIL quantification and distribution, in order to follow up
on whether morphological evaluation of TILs might reveal the underlying lymphocytic functional
connectivity and help relapse prediction.
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1. Introduction
Breast cancer accounts for 25% of all cancers in developed countries [1] and is the first cancer
world-wide affecting women, at a mean age of 64 years [2]. Apart from tumor staging and grading,
only a few reliable prognostic factors, such as hormone receptor and HER2 expression, are currently
available for breast cancer, to estimate the chance of disease recovery or relapse. New biomarkers
of risk and prognosis are therefore needed to guide and improve therapies toward a successful
clinical outcome.
The approach to identify new prognostic biomarkers is complex, because it must look at the
composite scenario of tumor progression and all its determinants, such as the critical interplay between
cancer cells and the immune microenvironment. Ever since Virchow (1863) and Paget (1889) pointed out
a connection between chronic inflammation and cancer development, the importance of the immune
microenvironment for cancer cell proliferation has gained more and more attention [3,4]. Today, it
is possible to monitor the tumor immune microenvironment by looking at the tumor-infiltrating
lymphocytes (TILs), which control tissue homeostasis and the activation of innate and adaptive
immune cells [5]. TILs are widely considered to be a key indicator of the immune interaction between
host and tumor, and potentially effective predictive biomarkers of cancer immunogenicity, clinical
outcome, response to immunotherapy and other antitumor treatments [5–11]. Although lymphocytic
infiltrates have long been observed in breast cancer, only recent clinical trials have demonstrated the
immunogenic nature of breast cancer and the potential role of host immunosurveillance in influencing
tumor progression and treatment responses [5,8,12–24]. B-cell infiltrates seem to play only a minor role
in mammary tumor, where CD20+ cells are sporadically detected [25,26]. In contrast, macrophages and
T-cells are very likely to be found within breast tumor, as TILs, as well as in the surrounding stroma,
as stromal tumor-infiltrating lymphocytes (STILs) [20]. Nevertheless, the actual function of lymphocytic
infiltrations is still debated, with several studies reporting discrepant results [5,27–30]. It is thought
that TILs play dual roles in cancer, by either suppressing or helping the immune responses; their
prognostic impact is further complicated by molecular subtypes and immune system variability [31].
On one hand, “suppressor” TIL subsets (e.g., FoxP3+, CD4+) can harbor immunosuppressive activity,
promote tumor invasion and restrict the effectiveness of immunotherapeutic strategies [29,30]; on the
other hand, “effector” TILs (e.g., CD3+, CD8+) have substantial anti-tumor and anti-proliferative
capabilities, and have been found to be associated with improved pathological response and better
clinical outcome [5,18,22,32–38].
The present study is intended to complement our previous investigations on
epithelial-to-mesenchymal transition (EMT) markers and cancer stem cells (CSCs) in normal
breast tissue and invasive breast cancer [39], and on the prognostic significance of Snail and FoxP3 in
invasive ductal breast cancer [31]. In those works, we already stated the existence of immunoactive cells
(CD3+, CD8+ and FoxP3+) in our cohort of patients, recognizing the further need to better determine
whether they may have an impact as prognostic biomarkers [31,39]. To this end, in the current work
we are going to characterize, quantify and investigate distribution and inter-/intra-correlations of TIL
subpopulations, in the same cohort of patients affected by invasive breast cancer [39].
By using morphological evaluation of TILs as main tool, we are seeking to reveal the lymphocytic
networks underpinning tumor immune microenvironment, and shed new light on their function and
prognostic impact.
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2. Results
2.1. Quantification and Distribution of TIL Subsets
We used antibodies that allowed us to identify the invasion of different types of lymphatic cells
in a breast cancer cell cluster. The pan-keratin antibody helped to identify all breast cancer cells
and distinguish them from stromal cells. A positive staining for the surface marker CD20 showed
all B-lymphocytes, while CD3 marked all T-lymphocytes. The cytotoxic T-cells were identified by
CD8 staining, while a positive reaction with a FoxP3 antibody showed only the regulatory T-cells
(Tregs). The Ki67 is a marker of cell proliferation, often correlated to cancer clinical course. This
combination of antibodies made it possible to detect the lymphatic cells in the cancer, identify them
and get information about their distribution and quantity. Lymphatic cells were found in the cancer as
well as in normal tissue, but TILs in normal breast tissue and ductal carcinoma in situ (DCIS) were not
counted. Representative examples are shown in Figure 1.
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Figure 1. Representative examples of the immunohistochemical staining of the lymphocyte markers
CD20, CD3, CD8, FoxP3, Ki67, for normal breast epithelium, DCIS and invasive breast cancer, the latter
divided in tumor center and margin.
There is currently no evidence showing hether TILs at the tumor edge functionally differ from
those located in the inner stroma, and to which extent tumor heterogeneity might be clinically relevant
in breast cancer [20]. In light of this, we evaluated TILs at the invasive edge as a separate parameter
from TILs in the tumor center, to investigate clinical implications of breast tumor heterogeneity,
in patients showing local or distant relapse of the tumor as well as in those without tumor recurrence.
In an invasive cancer formation, 0.15% B-lymphocytes (CD20+) were detected, while there were
3.78% T-cells (CD3+). Looking at the breast cancer infiltrati n of B-cells nd T-cells, no statistically
significant difference between tumor center and margin was found (CD3 p-value 0.263, CD20 p-value
0.127). Similarly, no statistically significant difference w s observed in th distrib ti n of cytotoxic
T-cells (CD8+) and Tregs (FoxP3+) between inner stroma and invasive edge of the tumor (CD8 p-value
0.409, FoxP3 p-value 0.232). Only few CD20+ cells and FoxP3+ cells were identified in both invasive
cancer and normal breast tissue, so that it was not always possible to take pictures with internal
positive controls (see Figure 1). Moreover, there was no statistically significant difference in the
incidence of all lymphatic cell types between the relapse and non-relapse group (p-values for: CD3
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0.825, CD8 0.137, CD20 0.447, FoxP3 0.801). Similarly, the Ki67 marker showed a homogeneous
distribution of the proliferating cells, since the proliferation rate was found not to be significantly
different neither comparing center to margin of the tumor (p-value 0.580) nor relapse to non-relapse
group (p-value 0.753).
Other sensitive indicators for monitoring immune function within tumor microenvironment
are the ratios of immune effector T cells (CD3+ and CD8+) to immune suppressor T cells (FOXP3+):
CD3+/FOXP3+ and CD8+/FOXP3+. Therefore, we analyzed the CD3+/FOXP3+ ratio, and found
no statistically significant difference neither between tumor margin and center (p-value 0.298) nor
between the relapse and non-relapse group (p-value 0.886). Similarly, looking at the CD8+/FOXP3+
ratio, no significant difference was observed neither between tumor edge and center (p-value 0.524)
nor between relapse and non-relapse group (p-value 0.334). The expression of all markers in invasive
breast cancer tissues is summarized in Table 1.
Table 1. Arithmetic average in percent (%) of TIL subpopulations (CD3+, CD8+, CD20+, FoxP3+,
Ki67+) and ratios (CD3/FoxP3, CD8/FoxP3) in invasive breast cancer samples. All the compared
groups and subgroups are listed with the respective p-value underneath.
Invasive Breast
Cancer Samples CD3 CD8 CD20 FoxP3 Ki67 CD3/FoxP3 CD8/FoxP3
All samples (n = 62) 3.8 1.58 0.15 0.54 11.77 3.73 1.78
Clinical groups
R (n = 26) 3.67 1.06 0.1 0.58 12.46 3.6 0.82
N (n = 36) 3.88 1.98 0.18 0.52 11.31 3.82 2.74
p 0.825 p 0.137 p 0.447 p 0.801 p 0.753 p 0.886 p 0.334
Topological groups
M (n = 31) 4.27 1.82 0.07 0.69 10.84 3.14 2.31
C (n = 31) 3.26 1.27 0.23 0.38 12.81 4.74 1.02
p 0.263 p 0.409 p 0.127 p 0.232 p 0.580 p 0.298 p 0.524
Subgroups
RM (n = 13) 4.02 1.14 0 0.84 11.42 2.7 0.76
NM (n = 18) 4.45 2.32 0.12 0.6 10.46 3.46 3.63
p 0.882 p 0.245 p 0.163 p 0.560 p 0.844 p 0.620 p 0.401
RC (n = 13) 3.3 0.98 0.2 0.33 13.59 5.11 0.9
NC (n = 18) 3.23 1.5 0.25 0.42 12.28 4.46 1.29
p 0.944 p 0.521 p 0.779 p 0.806 p 0.816 p 0.855 p 0.634
R = relapse group; N = non-relapse group; M = tumor margin; C = tumor center; RM = relapse tumor margin;
NM = non-relapse tumor margin; RC = relapse tumor center; NC = non-relapse tumor center; n = number.
The p-value is significant when <0.05 (no significant p-values are shown in Table 1).
2.2. Topological and Clinical Correlations between Different TIL Subsets
While looking for possible associations between different TIL subsets (inter-subtype correlations),
in the whole sample we observed three statistically significant positive correlations, as shown in
Figure 2: (1) between CD3+ and CD8+ lymphocyte infiltration (r = 0.392, p = 0.009); (2) between
FoxP3+ and Ki67+ lymphocyte infiltration (r = 0.337, p = 0.024); (3) between CD3+/FoxP3+ (C3FR)
and CD8+/FoxP3+ (C8FR) cell ratios (r = 0.560, p = 0.013).
Analyzing these correlations across topological groups, we further observed: (1) a significant
positive correlation between CD3+ and CD8+ TILs at the tumor center (r = 0.496, p = 0.031);
(2) a significant positive correlation between FoxP3+ TILs at the tumor center and Ki67+ TILs both
at the tumor center (r = 0.803, p = 0.000) and margin (r = 0.457, p = 0.043); (3) a significant positive
correlation between C3FR and C8FR at the invasive edge (r = 0.884, p = 0.000).
Moreover, we analyzed the same correlations across the clinical groups and subgroups, observing:
(1) a significant positive correlation between CD3+ and CD8+ TILs in the non-relapse group (r = 0.469,
p = 0.016); (2) a significant positive correlation between FoxP3+ and Ki67+ TILs in the non-relapse
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group (r = 0.550, p = 0.003), where, in particular, Ki67+ TILs at the tumor center were found to be
positively correlated with both FoxP3+ TILs at the tumor center (r = 0.887, p = 0.000) and FoxP3+ TILs
at the tumor margin (r = 0.582, p = 0.037); (3) a significant positive correlation was found between
C3FR and C8FR at the margin of the tumor not showing relapse (r = 0.911, p = 0.004).
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Figure 2. Scatterplot matrix (SPLOM) of correlations betweendifferent TIL subsets (CD8+, CD3+,
Ki67+, FoxP3+, CD20+), CD3+/FoxP3+ (C3FR) and CD8+/FoxP3+ (C8FR) cell ratios. Histograms of
the variables are shown in the diagonal. Only for SPLOM purposes, missing values were excluded
listwise, to obtain a consistent case base for the chart. * Correlation is significant at the 0.05 level
(2-tailed). ** Correlation is significant at the 0.01 level (2-tailed).
2.3. Topological and Clinical Correlations within TIL Subsets
While looking for possible associations within TIL subsets (intra-subtype correlations) across
the topological groups, we observed that CD3+, Ki67+ and FoxP3+ TILs at the tumor center were
positively correlated with their respective subsets at the tumor margin (CD3+ r = 0.647, p = 0.001; Ki67+
r = 0.778, p = 0.000; FoxP3+ r = 0.618, p = 0.006).
We then analyzed these significant associations across the clinical-topological subgroups, finding:
(1) a significant positive correlation between CD3+ TILs at the tumor center and CD3+ TILs at the
tumor margin, in b th the relapse (r = 0.694, p = 0. 38) and non-relapse (r = 0.632, p = 0.020) subgroups;
(2) a ignificant positive correlat on between Ki67+ TILs at the tumor center and Ki67+ TILs at the
tumor margin, in b th the relapse (r = 0.858, p = 0.001) and non-relapse (r = 0.724, p = 0.002) subgroups;
(3) a significant positive correlation between FoxP3+ TILs at the tumor center and FoxP3+ TILs at the
tumor margin, in the non-relapse subgroup (r = 0.738, p = 0.010).
All significant correlations, between and within TIL subsets, are listed in Table 2.
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Table 2. Significant correlations between different TIL subsets (inter-subtype correlations) and within
same TIL subsets (intra-subtype correlations) in invasive breast cancer, with their respective r coefficient,
p-value and sample size.
Significant Correlations Pearson Correlation(r Coefficient)
Significance
(2-Tailed) Value
Correlation’s
Sample Size
Inter-subtype correlations
CD3–CD8 0.392 0.009 ** 43
CD3c–CD8c 0.496 0.031 * 19
CD3n–CD3n 0.469 0.016 * 26
FoxP3–Ki67 0.337 0.024 * 45
FoxP3c–Ki67c 0.803 0.000 ** 21
FoxP3c–Ki67m 0.457 0.043 * 20
FoxP3n–Ki67n 0.55 0.003 ** 27
FoxP3nc–Ki67nc 0.887 0.000 ** 12
FoxP3nm–Ki67nc 0.582 0.037 * 13
C3FR–C8FR 0.56 0.013 * 19
C3FRm–C8FRm 0.884 0.000 ** 12
C3FRnm–C8FRnm 0.911 0.004 ** 7
Intra-subtype correlations
CD3c–CD3m 0.647 0.001 ** 22
CD3rc–CD3rm 0.694 0.038 * 9
CD3nc–CD3nm 0.632 0.020 * 13
Ki67c–Ki67m 0.778 0.000 ** 26
Ki67rc–Ki67rm 0.858 0.001 ** 10
Ki67nc–Ki67nm 0.724 0.002 ** 16
FoxP3c–FoxP3m 0.618 0.006 ** 18
FoxP3nc–FoxP3nm 0.738 0.010 ** 11
C3FR = CD3/FoxP3; C8FR = CD8/FoxP3; marks specify various clinical and/or topological groups/subgroups:
r = relapse; n = non-relapse; m = tumor margin; c = tumor center; rm = relapse tumor margin; nm = non-relapse
tumor margin; rc = relapse tumor center; nc = non-relapse tumor center; when no mark is specified, we refer to the
whole sample. * Correlation is significant at the 0.05 level (2-tailed). ** Correlation is significant at the 0.01 level
(2-tailed).
3. Discussion
3.1. Quantification and Distribution of TIL Subsets
In our cohort of invasive breast cancer patients, TILs represented the 3.78% on average of the
tumor mass, FoxP3+ TILs the 0.55%, and occurred with an equal distribution in the tumor center and
margin. A plausible reason why we rarely found Tregs in the analyzed tissues might be the early stage
of the investigated breast tumors, mainly T1 N0 M0. In fact, FoxP3+ cells are more often detected
in advanced tumor stages with lymph node involvement [40,41], and are likely to be located in the
surrounding stroma [25], which we did not consider in the present study. We separately evaluated
TILs at the invasive edge and TILs at the center of the tumor, to find any clinical implications of tumor
heterogeneity. No statistically significant differences of quantity and distribution of both TIL subsets
and TIL ratios were found, either when comparing topological and clinical groups and subgroups.
Although the clinical groups were matched for histological subtype, tumor stage and hormone
receptor status, the distribution of the hormone receptor status between the two cohorts was not equal.
This factor could represent a limitation for a comparative analysis, given breast cancer heterogeneity
and the different impact of the immune infiltrate on outcome across breast cancer subtypes. As such,
the presence of TILs was shown to be potentially prognostic in triple-negative breast cancer (TNBC)
and human epidermal growth factor receptor 2 (HER2)–positive patients [42]. In those tumor subtypes,
higher levels of TILs were observed to be associated with better overall survival and fewer recurrences,
independently from the therapy [21,34,43] and the immune subpopulations of the infiltrate [13,34,43,44].
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Nevertheless, the functionality of various TILs and their composition should also be taken into account
for a complete breast cancer assessment and management [42].
3.2. Topological and Clinical TIL Inter-/Intra-Subtype Correlations
Despite the lack of prognostic impact of the quantity and the distribution of the single TIL
subsets, we found the analysis of correlations between and within TIL subtypes to be more crucial for
understanding how the tumor immune microenvironment differs between relapse and non-relapse
patients. Inter-subtype lymphocytic correlations (between CD3-CD8, FoxP3-Ki67, C3FR-C8FR) were
significant only in the non-relapse group, while intra-subtype lymphocytic correlations (within CD3,
Ki67) were found to be significant in both relapse and non-relapse groups. This may suggest the
existence of stronger inter-subtype lymphocytic networks in invasive breast cancer without recurrence,
which might have a role in preventing relapse.
In the following, we discuss our findings in the context of the current literature, providing a
concise background of those TIL subsets showing significant correlations in our patients.
3.2.1. The Effector TILs
There is already evidence of the positive prognostic impact of both CD3 and CD8 markers in large
cohorts of estrogen-negative or triple-negative breast cancer (TNBC) [32–34]. Furthermore, CD3 was
found to be an independent marker of good prognosis in ductal breast cancer [36] and correlated to a
better overall survival [35,45]. Similarly, CD8 was observed to be a strong prognostic factor for risk
stratification in breast cancer patients [37], leading to better prognosis, recurrence-free, cancer-specific
survival [12,18] and clinical outcome [37,38]. In our previous study [31], the expression of CD3+
and CD8+ lymphocytes had no statistically impact on disease-free and overall survival in invasive
ductal breast cancer. Likewise, in our current study, although higher CD3 and CD8 expressions were
observed in the non-relapse group, no statistically significant difference of quantity and distribution
was found by comparing topological as well as clinical groups. There was, however, a significant
positive correlation between CD3+ and CD8+ T-cells at the tumor center in the non-relapse group,
suggesting a possible role of CD3-CD8 lymphocytic network in preventing recurrence.
3.2.2. The Suppressor TILs
Findings on FoxP3+ TILs are still not consistent: in our previous work on invasive ductal breast
cancer [31], FoxP3 was an independent prognostic factor of disease-free and overall survival, while
other studies on mammary cancer observed a connection of high FoxP3 expression with reduced
progression-free and overall survival [46,47]. Moreover, a high number of FoxP3+ cells was found to
be associated with a poor prognosis, increased invasiveness and probability of metastasis occurrence
in several solid tumors [40,48–50], such as renal cell carcinoma [51] and ovarian cancer [52]. FoxP3
is also more likely to be an indicator of tumor-induced immune evasion [31], since FoxP3+ cells are
responsible for inactivation of tumor-specific immune defense [40,53] and autoreactive T lymphocytes,
such as CD8+ cells [19,40,54]. In the present study, a similar FoxP3 expression was observed in both
relapse and non-relapse patients. However, the non-relapse group showed a positive intra-subtype
TIL correlation between FoxP3+ cells at tumor margin and center, as well as a positive inter-subtype
TIL correlation between FoxP3+ and Ki67+ cells. Overall, patients without relapse exhibited several
significant correlations of both suppressor (CD3+, CD8+) and effector (FoxP3+) TILs, suggesting that
strong lymphocytic networks, independently from their suppressor/effector nature, underpin tumor
balance, with a less connected and wired tumor immune microenvironment potentially increasing the
risk of relapse.
3.2.3. The Effector to Suppressor TIL Ratios
To have a more complete picture of the tumor immune microenvironment, we also evaluated
the ratios (CFRs) of effector T-cells (CD3+, CD8+) to suppressor T-cells (FoxP3+), as prognostic
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variables. The importance of CFRs as prognostic biomarkers has been shown in previous studies
on solid tumors, including breast cancer. Low intraepithelial C3FR was found to be correlated with
shorter patient survival time in colon cancer [55] and with adverse outcomes in early-stage non-small
cell lung cancer [56]. Similarly, the C8FR was an independent prognostic factor in colorectal tumor
and a predictive marker for both disease-free and overall survival times [50]. A lower C8FR was
associated with adverse outcome in patients with ovarian cancer [57] and hepatocellular carcinoma [58];
while a higher C8FR had a positive prognostic impact on serous ovarian cancer [59]. Importantly,
the C8FR was recently shown to be a valid biomarker also in breast cancer [12,18,19]. It was a useful
predictor of treatment response to neoadjuvant therapy in aggressive breast cancer subtypes [19],
of relapse of ductal carcinoma in situ (DCIS) [12], and of prognosis in TNBC patients [18]. A lower
C8FR was associated with the probability of relapse [12], while a higher C8FR predicted favorable
prognosis [18,19]. In the present study, although higher CFRs were observed in the non-relapse group,
no statistically significant difference of quantity and distribution was found by comparing topological
as well as clinical groups. This may mean that the presence of both effector and suppressor TILs was
similar in tumor margin and center, in relapse and non-relapse conditions. Nevertheless, a strong
tumor heterogeneity was observed in the significant TIL correlations exhibited by the non-relapse
group: CD3+ and CD8+ lymphocytic infiltrations were found to be positively inter-correlated at
the tumor center, while C3FR and C8FR showed a positive correlation at the invasive edge of the
tumor. These findings might be indicative of the presence of two different protective networks
against relapse: a protective “effector” TIL network (CD3–CD8) at the tumor center, as well as a
protective “effector/suppressor” TIL balance (C3FR–C8FR) at the tumor margin, possibly relevant to
keep relapse-initiating CSCs and EMT dormant.
4. Materials and Methods
4.1. Cohort and Sample Selection
In this retrospective study, patients were selected among those treated for invasive breast cancer,
between July 2008 and September 2009, at the Breast Cancer Center of the Department of Gynecology
and Obstetrics, University Hospital Schleswig-Holstein, Campus Kiel, Germany. Written informed
consent was available for all patients and approved by the ethics committee.
Carcinomas were classified according to the criteria of the World Health Organization. Staging at
the time of diagnosis was based on the TNM (tumor, node and metastasis) system [60]. The selection
criteria were: (a) tumor size and (b) availability of high-quality formalin-fixed paraffin-embedded
tissue (FFPE). Tumors less than 2 cm in diameter were included in the study, to reliably distinguish
between tumor center and tumor margin/invasion front on one full slide of the tumor. Thirteen
patients out of those registered at the Breast Cancer Database fulfilled the selection criteria and were
included in the relapse group, suffering from a local or distant recurrence of the tumor.
Eighteen patients were selected for the non-relapse group, suffering from an invasive breast cancer
without showing local or distant recurrence of the tumor during a median follow-up of 54 months
(range 36–132 months). They matched the relapse group by histological subtype, tumor stage and receptor
expression (estrogen and progesterone receptors’ expression ≥ score 3), as shown in Table 3.
None of the patients in the relapse or non-relapse groups underwent preoperative radiation or
chemotherapy. All patients received appropriate postoperative treatment depending on the stage of
the disease, including chemotherapy, radiation and medical anti-estrogen therapy, when indicated.
The clinical parameters and prognostic factors (tumor staging; histological type; tumor grading;
hormone receptor status: estrogen receptor, progesterone receptor, Her2neu status) of the relapse and
non-relapse groups are outlined in Table 3, where absolute as well as relative frequencies are provided.
DCIS, normal breast tissue adjacent to the tumor as well as tissue from breast reduction were
analyzed as further controls.
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Table 3. Clinicopathological parameters and of the relapse (R) and non-relapse (NR) group.
Parameters
R Group’s
Absolute
Frequency (n = 13)
R Group’s
Relative
Frequency %
NR Group’s
Absolute
Frequency (n = 18)
NR Group’s
Relative
Frequency %
TNM classification
T1 13 100 18 100
N0 10 76.9 18 100
M0 11 84.6 16 88.9
Histological type
Ductal 8 61.5 14 77.8
Lobular 2 15.4 3 16.7
Other 3 23.1 1 5.6
Tumor grade
≤G2 8 61.5 12 66.7
Receptor
expression
ER+ ≥ 3 7 53.8 15 83.3
PR+ ≥ 3 6 46.1 12 66.7
Her2neu ≥ 2 2 15.4 4 22.2
Patients’ age
Mean 51 55
Max 68 72
Min 36 36
Time of follow-up * 99 54
R = relapse; NR = non-relapse; T1 = T1 stage (tumor size ≤ 2 cm across); N0 = N0 stage (no cancer cells in any
nearby nodes); M0 = M0 stage (no distant metastasis); ≤G2 = grade 2 or 1 (well/moderately differentiated cancer
cells); ER+ ≥ 3 = estrogen receptor expression ≥ score 3; PR+ ≥ 3 = progesterone receptor expression ≥ score 3;
n = total number; * median of follow-up duration in months.
4.2. Tissue Micro Arrays (TMA)
FFPE specimens were retrieved from the archives of the Department of Pathology. Histological
examination was performed with hematoxylin and eosin staining (H&E) and representative areas
were selected and assembled in a tissue microarray (TMA), using cores of 1.0 mm diameter and a
TMA1 Tissue Arrayer (Beecher Instruments, Sun Prairie, WI, USA). Areas in the tumor center and
the invasion front were selected and punched independently, with the distance between both areas
being >2 mm.
4.3. Immunohistochemistry
Three µm sections of the TMA were used for immunohistochemistry. Antigen retrieval was
performed for the FoxP3 antibody manually, with an EDTA buffer pH8 for 3 min, by boiling in
a pressure cooker. The primary antibody was applied for one hour at room temperature (mouse,
monoclonal FoxP3 antibody, 1:250, pH8, Abcam, Cambridge, UK). The secondary antibody (Histofine:
Simple MAX PO (Multi) Universal Immuno-peroxidase Polymer produced by Medac, (Chicago, IL,
USA) was applied for 30min at room temperature. The detection was performed using 100 µL/slide
Dako DAB (Agilent, Santa Clara, CA, USA).
The antibodies for CD3 (rabbit, monoclonal CD3 antibody, 1:100, pH6, NeoMarkers, (Portsmouth,
NH, USA), CD8 (mouse, monoclonal CD8 antibody, 1:100, pH6, Dako), CD20 (mouse, monoclonal
CD20 antibody, 1:5, pH6, own production), Ki67 (mouse, monoclonal Ki67 antibody, 1:5, pH6, own
production) and pan-keratin (mouse, monoclonal pan-keratin antibody, 1:200, pH8, NeoMarkers) were
applied by the Bond MAX system of Leica and the detection system Bond Polymer Refine Detection
(Leica Biosystems Newcastle, United Kingdom, catalog No: DS9800). Firstly, the tissues were incubated
in hydrogen peroxide to quench endogenous peroxidase activity; then, the antigen retrieval was either
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done with a citrate buffer pH6 or with pH8 EDTA buffer. The incubation of the primary antibody with
the Bond MAX system takes 15 min. A post primary IgG linker is used to detect the primary antibody.
Subsequently a Poly-HRP IgG reagent localizes the antibody complex for heightening the staining
intensity. Furthermore, in the automatic staining 3,3′-diaminobenzidine tetrahydrochloride (DAB)
and hematoxylin counterstaining were used for the visualization. For negative controls, the primary
antibodies were omitted. The tissue was analyzed by light microscopy (Zeiss Axiophot, Zeiss GmbH,
Jena, Germany) and reviewed by ProCapture software (Mawson Lakes, South Australia). Only positive
stained cells in a cluster of cancer cells were assessed and counted manually, to determine the
percentage of lymphatic cells in the tumor. 100 cells of a tumor cluster in every TMA Core were
counted and the number of containing lymphatic cells was determined. Data on hormone receptor
status were scored following immunohistochemistry staining guidelines of the American Society of
Clinical Oncology and College of American Pathologists [61,62].
4.4. Ethics Statement
This study was approved by the Ethical Committee of the Christian-Albrechts-University Kiel,
Kiel, Germany (D 426/10; 31 August 2010). The board chairman is Professor H.M. Mehdorn and the
managing director is C. Glienicke. All the living patients signed an informed consent to allow the use
of their tumor specimen and clinical data.
4.5. Statistical Analysis
All statistical analyses were carried out in SPSS® version 23 statistical software (IBM, Armonk,
NY, USA). Group comparisons were done by performing independent-samples t-tests. Correlations
between and within variables were revealed by running bivariate Pearson Correlation. Cases with
missing values were excluded on an analysis-by-analysis basis (pairwise deletion).
5. Conclusions
In evaluating TILs in invasive breast cancer, quantity and distribution of single TIL subsets
did not show any prognostic impact on our patients. In contrast, we found statistically significant
correlations between and within TIL subtypes to be indicative of the extent to which the tumor immune
microenvironment differed between relapse and non-relapse conditions.
(1) Patients without relapse exhibited several significant correlations of both suppressor (CD3,
CD8) and effector (FoxP3) TILs, suggesting that the presence of strong lymphocytic networks
might have a role in maintaining the tumor lymphocytic balance, meaning that a less wired and
connected tumor immune microenvironment might be more prone to relapse.
(2) Inter-subtype lymphocytic correlations (between CD3–CD8, FoxP3–Ki67, C3FR–C8FR) were
significant only in the non-relapse group, while intra-subtype lymphocytic correlations (within
CD3, Ki67) were found to be significant in both clinical groups. This may suggest that in particular
the presence of strong inter-subtype lymphocytic networks might play a role in preventing breast
cancer recurrence.
(3) Moreover, the non-relapse group exhibited tumor heterogeneity in terms of distribution of
lymphocytic networks. In fact, a significant positive correlation was found between CD3+ and
CD8+ T-cells at the tumor center, whereas C3FR and C8FR were found to be positively correlated
at the invasive edge of the tumor. This may suggest the presence of two different protective
networks: a protective “effector” TIL network (CD3–CD8) at the tumor center, as well as a
protective “effector/suppressor” TIL balance (C3FR–C8FR) at the tumor margin, possibly to
control relapse-initiating CSCs and EMT.
Further evaluations of clinical and topological correlations between and within TIL subsets
are needed, in addition to TIL quantification and distribution, to further investigate whether
morphological evaluation of TILs might reveal the underlying tumor lymphocytic connectivity.
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A deeper understanding of breast tumor immunogenicity and lymphocytic networks can shed
new light on tumor progression mechanisms, further the development of more effective prognosis
techniques and improve treatment responses.
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